This study investigated the psychological characteristics and clinical features of 55 patients with geriatric depression, and evaluated the efficacy and safety of escitalopram in the treatment of geriatric depression, in a randomized controlled trial. Fifty-five patients with geriatric depression were randomly assigned to receive 8 weeks of escitalopram 10 mg, daily, orally (n = 29) or placebo (n = 26). At baseline, these patients had significantly higher neuroticism and psychoticism scores on the Eysenck Personality Questionnaire -Adult scale than Chinese population norms. General Severity Index scores and the mean values of the nine subscales of the Symptom Checklist-90 -Revised scale were also significantly higher in these patients than in Chinese population norms. The response rate to escitalopram after 8 weeks' treatment was 74.1% (20/27 patients). Adverse reactions included nausea, dry mouth and dizziness. In conclusion, depressed geriatric patients were found to have abnormal personality traits, and escitalopram was efficacious and had a good safety profile in the treatment of geriatric depression.
Introduction
Geriatric depression is a common mental disorder in the elderly population, but often goes unrecognized and is inadequately treated. 1 It may result in impaired physical, mental and social functioning, which places a heavy burden on society and individuals. 2, 3 Thus, it is important to recognize and treat geriatric depression properly.
The present randomized controlled study used several psychological scales and diagnostic criteria to investigate the personality, psychological characteristics and clinical features of patients with geriatric depression, and assessed the efficacy and safety of escitalopram, a selective serotonin reuptake inhibitor (SSRI), 4 in the treatment of geriatric depression.
Patients and methods

PATIENTS
This study was conducted at the Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China, between April a Y-M Chen and X-M Huang both contributed equally to this work. Escitalopram demonstrates efficacy in geriatric depression 2009 and June 2010. To be included in the study, subjects had to meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 5 criteria for major depression, be ≥ 65 years old and have a score of ≥ 20 on the Geriatric Depression Scale (GDS). 6, 7 Subjects were excluded if they met DSM-IV criteria for bipolar disorder, had secondary depression caused by organic brain diseases or other physical diseases, had a diagnosis of dementia, were currently receiving antidepressant treatment, had a history of alcohol or drug abuse, or had a clinically significant laboratory abnormality.
The study was approved by the Ethics Committee of Shanghai First People's Hospital, Shanghai Jiao Tong University. Written informed consent was obtained from all participants.
STUDY DESIGN
Before enrolling in the study, all patients underwent a physical examination and laboratory tests. For the baseline evaluations, all patients were assessed using the following psychological scales: Eysenck Personality Questionnaire -Adult (EPQ-A), 8 Symptom Checklist-90 -Revised (SCL-90-R); 9 GDS; and Clinical Global Impressions -Severity of Illness (CGI-SI). 10 After an initial evaluation, all patients were randomly assigned, according to a computer-generated randomization schedule, to receive escitalopram at 10 mg, daily, orally, or a matching placebo. The treatment period lasted for 8 weeks and the outcome and safety assessments were performed every 4 weeks throughout the treatment period.
OUTCOME MEASURES
The primary outcome measure was the change in the GDS score from baseline to week 8. Efficacy was assessed by the percentage reduction in the GDS score (100 × [pretreatment score − post-treatment score] / pretreatment score) as invalid (≤ 25%), improvement (26 -50%), considerable improvement (51 -75%) and clinical cure (≥ 75%).
The secondary outcome measure was the change in the CGI-SI score from baseline to week 8. A physical examination and laboratory tests were performed at each visit. Adverse reactions were reported spontaneously by patients.
STATISTICAL ANALYSES
All analyses were conducted using the SPSS ® statistical package, version 18.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A Student's t-test was used to compare data from study patients with Chinese population norms 11, 12 at baseline for the EPQ-A and SCL-90-R scores. Analysis of covariance was used to compare the GDS and CGI-SI scores between baseline and weeks 4 or 8 within each group, and to compare GDS and CGI-SI scores at weeks 4 or 8 between the escitalopram and placebo groups. A P-value < 0.05 was considered to be statistically significant.
Results
DEMOGRAPHIC DATA
A total of 55 patients (21 males [38.2%] and 34 females [61.8%]) who met the inclusion criteria were evaluated and enrolled in the study. The mean ± SD age of the patients was 68.9 ± 6.1 years (range 65 -79 years). The mean ± SD duration of depression was 4.1 ± 2.8 months (range 0.5 -36 months), and the mean ± SD scores for GDS and CGI-SI were 23.83 ± 5.72 (range 20 -28) and 5.41 ± 1.11 (range 4 -7), respectively. A total of 29 patients were assigned to the escitalopram group and 26 patients to the placebo group. There were no differences in sex, age, disease duration and depression severity between the two groups (data not shown).
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BASELINE CHARACTERISTICS
The personality traits of the 55 patients were assessed using EPQ-A. The results for both male and female geriatric depressed patients showed that neuroticism and psychoticism scores were significantly higher in these patients than in the Chinese population norms (P < 0.01) ( Table 1) . 11, 12 The extroversion and introversion scores in both male and female geriatric depressed patients were significantly lower than the Chinese population norms (P < 0.05), whereas the scores of the fourth scale, the lie score, showed no statistical difference compared with the Chinese population norms. 11, 12 The psychological characteristics of the patients were also examined using SCL-90-R. The General Severity Index (GSI), Positive Symptom Distress Index (PSDI), Positive Symptoms Total (PST) and the mean values of the nine subscales of the patients were significantly higher than the Chinese population norms (P < 0.01) ( Table 2) . 11, 12 The clinical symptoms of the geriatric depressed patients included depressed mood, somatic symptoms and sleep disorders. The somatic symptoms consisted of headache, dizziness, tinnitus, muscle weakness, muscle pain, autonomic symptoms and other nervous system symptoms. Some patients showed several symptoms at the same time. Importantly, 23 patients (41.8%) had suicidal ideation and eight patients (14.5%) had made a suicide attempt.
EFFICACY OF ESCITALOPRAM
A total of 51 of the 55 patients completed the 8-week therapeutic trial. Four patients (two assigned to each group) were lost to followup and were not included in the analyses.
The results showed that the GDS and CGI-SI scores between the escitalopram and placebo groups were not significantly different at baseline (Tables 3 and 4 ). At weeks 4 and 8, the GDS and CGI-SI scores of the escitalopram group were significantly decreased compared with baseline (P < 0.05 and P < 0.01, respectively, at both weeks 4 and 8), while the GDS and CGI-SI scores of the placebo group showed no significant difference, compared with baseline. Additionally, the GDS and CGI-SI scores of the escitalopram group were significantly lower than those of the placebo group at week 4 and week 8 (P < 0.05).
Escitalopram treatment resulted in significant clinical improvement: the difference in efficacy between escitalopram 
ADVERSE REACTIONS
Six of the 27 patients (22.2%) evaluated in the escitalopram group showed mild adverse reactions (such as nausea, dry mouth and dizziness) in the first 2 weeks of treatment, which were relieved or disappeared spontaneously in the following 2 weeks. No severe adverse reactions were observed during escitalopram treatment. One of the 24 patients (4.2%) evaluated in the placebo group had nausea in the first week. The abnormality rates in laboratory tests for all patients showed no significant differences before and after treatment.
Discussion
Geriatric depression is depression that occurs during old age (≥ 65 years) and it includes primary depression (including youth or adult-onset depression that recurs in old age) and secondary depression. 13 -15 Primary depression is generally caused by biological and neurochemical changes in the brain and nervous system or by changes in the endocrine system. 16 Secondary depression refers to the depression that is caused by other diseases or medications. 16 Patients with primary geriatric depression were selected for The association between personality and geriatric depression was investigated. The EPQ-A personality analysis of the patients showed that the scores of two dimensionsneuroticism and psychoticism -were significantly higher in geriatric depressed patients than in the Chinese population norms, while the scores for extroversion and introversion were significantly lower than those in the Chinese population norms. This suggests that geriatric depressed patients have increased emotional instability and increased vulnerability to psychosis and low extroversion compared with the Chinese population norms. Elderly people with these personality traits may be more sensitive to various social and psychological factors and may be more likely to have geriatric depression compared with the Chinese population norms.
The GSI, PSDI, PST and the mean values of the nine subscales of SCL-90-R for the 55 patients were significantly higher than the Chinese population norms. The mean values for somatization, depression and anxiety were higher compared with the Chinese population norms, indicating that geriatric depressed patients have various mental abnormalities.
The clinical symptoms of geriatric depression were found to be complex: the most common symptoms included depressed mood, somatic symptoms and sleep disorders. In the early stages of geriatric depression, patients often have a variety of somatic symptoms, while their mood disorders are easily neglected by their families.
It was shown that 23 patients (41.8%) had suicidal ideation and eight patients (14.5%) had made a suicide attempt. Geriatric depressed patients are at a much greater risk of suicide than any other age group. 17 The risk factors for suicide include loneliness, depression, agitation and hypochondriasis. The issue of suicide in geriatric depression merits considerable attention.
Escitalopram was selected to treat geriatric depression in the present study. It is a very selective SSRI, with very little effect on other neurotransmitters and receptors. 18 -20 Escitalopram does not inhibit its own metabolism and its metabolites have no effect on the metabolism of the parent drug, so its long-term use will not lead to accumulation in the body. 21 Escitalopram has less effect on the hepatic cytochrome P450 isoenzyme system than other SSRIs and it has minimal potential for drug-drug interactions. 22, 23 The oral dose range of escitalopram is 10 -50 mg/day, and its potential adverse reactions include somnolence and mild gastrointestinal reactions. 24, 25 Escitalopram has little sedative effect, 26 so it may be appropriate to combine escitalopram with sedative hypnotics to treat those depressed patients who have sleep disorders.
In the present study, patients who received escitalopram at a dose of 10 mg/day showed significantly greater improvement compared with those in the placebo group. The GDS scores had decreased by 38.2% at the end of week 4, indicating that escitalopram has a rapid onset of effect in the treatment of geriatric depression. The relative reduction rate of the GDS scores increased throughout the treatment period. After 8 weeks of treatment, the results showed that the clinical cure rate associated with escitalopram treatment was 40.7% and the overall response rate was 74.1%, indicating that escitalopram was efficacious in the treatment of geriatric depression.
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• Revised accepted 29 July 2011 Copyright © 2011 Field House Publishing LLP reactions (such as nausea, dry mouth and dizziness) during the treatment period, but all of the reactions were mild and were relieved or disappeared spontaneously. Furthermore, the abnormality rates in laboratory tests for all patients showed no significant differences before and after treatment, indicating that escitalopram was well tolerated and had a good safety profile in the treatment of geriatric depression.
In conclusion, geriatric depressed patients have high levels of neuroticism and psychoticism and low levels of extroversion. Escitalopram was efficacious in the treatment of geriatric depression without serious adverse reactions, supporting the use of escitalopram in the elderly population with major depression.
